AZD3480 exhibited an overall safety and tolerability profile comparable to placebo in the study generic drugs.

AZD3480 exhibited an overall safety and tolerability profile comparable to placebo in the study, with fewer gastrointestinal side effects than donepezil generic drugs .

AstraZeneca and Targacept Announce Top-line Results from Phase 2b Study Of AZD3480 In Alzheimer’s diseaseAbout the StudyThe Phase 2b study Sirocco by AstraZeneca under the terms of an exclusive global license and research collaboration was performed. The study was performed a multicenter, randomized, double blind, placebo-controlled, dose-ranging study at 84 sites in Western Europe, Eastern Europe and Canada. Subjects were between 60 and 85 years and diagnosed with probable Alzheimer’s disease, classified, was based on a quantitative scale, as mild or moderate. The subjects were assigned to one of three groups of AZD3480 dose to an active comparator, donepezil or placebo and dosed for 12 weeks. The primary endpoint in the study was the change from baseline after 12 weeks on ADAS-Cog. A number of secondary endpoints were also used in the study.

ed drugs

ASN and SPC collaboration with NIH , to keep the ASN ASP Conference on predict, progressive and outcomes Chronic Kidney Disease Chronic Kidney Disease older adults. The workshop May 2008 in May 2008 would to enhance NIH financing on the geriatric issues of nephrology. ASP ASN available funding of four scholarships attend and participate in the workshop.

New research proposing, if used properly, vibration plate fitness equipment can help losing weight and trim the especially harmful belly fat between the organs.

Other articles from category "psychotherapy":

Random articles